Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

RA Capital Management

Founders Richard Aldrich

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 427
Average round size
info
The average size of a deal this fund participated in
$85M
Portfolio companies 305
Rounds per year 18.57
Lead investments 77
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.29
Exits 123
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical
Summary

RA Capital Management appeared to be the VC, which was created in 2001. The leading representative office of defined VC is situated in the Boston. The venture was found in North America in United States.

The typical case for the fund is to invest in rounds with 6-7 participants. Despite the RA Capital Management, startups are often financed by OrbiMed, F-Prime Capital, Flybridge Capital Partners. The meaningful sponsors for the fund in investment in the same round are Wellington Management, Longitude Capital, Deerfield. In the next rounds fund is usually obtained by OrbiMed, Cormorant Asset Management, Polaris Partners.

Opposing the other organizations, this RA Capital Management works on 23 percentage points more the average amount of lead investments. The fund is generally included in 7-12 deals every year. The real fund results show that this VC is 4 percentage points more often commits exit comparing to other companies. The average startup value when the investment from RA Capital Management is more than 1 billion dollars. The increased amount of exits for fund were in 2015. The important activity for fund was in 2015. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 50 - 100 millions dollars.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the various public portfolio startups of the fund, we may underline AveXis, Moderna Therapeutics, Intarcia Therapeutics Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Health Care, Health Diagnostics.

This organization was formed by Richard Aldrich. We also calculated 4 valuable employees in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of RA Capital Management:
Typical Co-investors
RA Capital Management is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after RA Capital Management:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Alpha9 Theranostics

Biotechnology
Medical
Product Research
23 Oct 2024 Vancouver, British Columbia, Canada

Enara Bio

Biotechnology
Therapeutics
03 Oct 2024 London, England, United Kingdom

Aktis Oncology

Biotechnology
Life Science
30 Sep 2024 Boston, Massachusetts, United States

Superluminal Medicines

Biotechnology
Medical
Pharmaceutical
$120M09 Sep 2024 Boston, Massachusetts, United States

Navigator Medicines

Biotechnology
Life Science
$100M27 Aug 2024 Scotch Plains, New Jersey, United States

Halda Therapeutics

$126M12 Aug 2024 Branford, Connecticut, United States

Idrx

Biotechnology
Life Science
Product Research
$120M07 Aug 2024 -

MBX Biosciences

Biotechnology
Health Care
Wellness
$63M05 Aug 2024 Indiana, United States

Outpace Bio

Biotechnology
Health Care
Life Science
Pharmaceutical
$144M01 Aug 2024 Seattle, Washington, United States
News
Obsidian Therapeutics Closes $115M Series B Financing

– Obsidian Therapeutics, Inc. is a Cambridge, Mass.-based biotechnology company pioneering engineered cell and gene therapies.
– The company closed a $115m Series B financing.
– The round was led by The Column Group Crossover Fund (TCGX) with participation from RA Capital Management, Surveyor Capital (a Citadel company), Cowen Healthcare Investments, Deep Track Capital, Logos Capital, Pivotal BioVenture Partners, Samsara BioCapital, and Soleus Capital, and existing investors Atlas Venture, Vertex Ventures HC, Amgen Ventures, and Bristol Myers Squibb.
– Proceeds from the financing will be used to drive Obsidian’s lead tumor infiltrating lymphocyte (TIL) program, cytoTIL15, into the clinic and to first clinical data for the treatment of metastatic melanoma. In addition, the company plans to rapidly expand cytoTIL15 into multiple other solid tumor types and to advance its commercial manufacturing build.

HilleVax Closes $135 Million Crossover Financing to Advance Clinical Stage Norovirus Vaccine Candidate

– HilleVax, Inc. (HilleVax), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, announced the close of a $135 million crossover financing led by Frazier Healthcare Partners and joined by RA Capital Management, Deerfield Management Company, Abingworth, Lightspeed Venture Partners, Perceptive Advisors, Catalys Pacific, Samsara BioCapital, BVF Partners, Qiming Venture Partners USA, Greenspring Associates, Richard King Mellon Foundation, and Sahsen Ventures.
– The proceeds of this financing support the further clinical development of HilleVax’s virus-like particle (VLP) based vaccine candidate, HIL-214, for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent RA Capital Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 427
Average round size 85M
Rounds per year 18.57
Peak activity year 2021
Lead investments 77
Follow on index 0.29
Exits 123
Group Appearance index 0.95

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Alpha9 Theranostics

Biotechnology
Medical
Product Research
23 Oct 2024 Vancouver, British Columbia, Canada

Enara Bio

Biotechnology
Therapeutics
03 Oct 2024 London, England, United Kingdom

Aktis Oncology

Biotechnology
Life Science
30 Sep 2024 Boston, Massachusetts, United States

Superluminal Medicines

Biotechnology
Medical
Pharmaceutical
$120M09 Sep 2024 Boston, Massachusetts, United States

Navigator Medicines

Biotechnology
Life Science
$100M27 Aug 2024 Scotch Plains, New Jersey, United States

Halda Therapeutics

$126M12 Aug 2024 Branford, Connecticut, United States

Idrx

Biotechnology
Life Science
Product Research
$120M07 Aug 2024 -

MBX Biosciences

Biotechnology
Health Care
Wellness
$63M05 Aug 2024 Indiana, United States

Outpace Bio

Biotechnology
Health Care
Life Science
Pharmaceutical
$144M01 Aug 2024 Seattle, Washington, United States
Crunchbase icon

Content report

The following text will be sent to our editors: